Get the Stockscreener App
13.59
1.52%
-0.205
Wave Life Sciences Ltd stock is traded at $13.59, with a volume of 408.66K.
It is down -1.52% in the last 24 hours and up +61.47% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$13.79
Open:
$13.84
24h Volume:
408.66K
Relative Volume:
0.25
Market Cap:
$2.05B
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-9.989
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
-8.24%
1M Performance:
+61.47%
6M Performance:
+121.17%
1Y Performance:
+140.78%
1-Day Range:
$13.42
$13.88
1-Week Range:
$13.14
$14.77
52-Week Range:
$3.50
$15.92
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 - StockTitan
B. Riley Increases Wave Life Sciences (NASDAQ:WVE) Price Target to $22.00 - MarketBeat
Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Emerald Advisers LLC Purchases 388,280 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences' (WVE) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Those who invested in Wave Life Sciences (NASDAQ:WVE) three years ago are up 195% - Simply Wall St
Wave Life Sciences Highlights Growing Pipeline at Research - GlobeNewswire
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs - StockTitan
How to play biotech stocks: Insmed and Wave Life Sciences - Yahoo Finance
Analysts Set Wave Life Sciences Ltd. (NASDAQ:WVE) Target Price at $19.44 - MarketBeat
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know - Yahoo Finance
(WVE) Technical Data - Stock Traders Daily
Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering - MSN
Can Wave Life Sciences Make Waves With Forward-53 DMD Trial Data? - RTTNews
Asia Deal Watch: Cureverse Licenses Option For Neurology Candidate To Angelini - Scrip
WAVE Life Sciences (STU:1U5) Growth Rank : 2 (As of Oct. 25, 2024) - GuruFocus.com
WaVe Life Sciences' SWOT analysis: RNA editing pioneer's stock faces pivotal trials - Investing.com India
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Moody Aldrich Partners LLC - MarketBeat
1 Brand-New Big Reason to Buy This Biotech Stock Right Now - Yahoo Finance
VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now? - Yahoo Finance
RBC Capital raises WAVE Life Sciences stock target By Investing.com - Investing.com Australia
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast - BioCentury
Wave Life Sciences (NASDAQ:WVE) PT Raised to $15.00 at Royal Bank of Canada - MarketBeat
Wave Life Sciences Rockets 70% on Historic RNA Editing Success - MSN
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? - Benzinga
SG Americas Securities LLC Has $300,000 Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data - MSN
Insider Sale: President and CEO Paul Bolno Sells 90,474 Shares o - GuruFocus.com
Wave Life Sciences' Chris Francis sells $2.86 million in shares By Investing.com - Investing.com Australia
Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno Sells 90,474 Shares - MarketBeat
Wave Life Sciences CEO Paul Bolno sells $1.36 million in shares By Investing.com - Investing.com South Africa
Wave Life Sciences CEO Paul Bolno sells $1.36 million in shares - Investing.com
Wave Life Sciences' Chris Francis sells $2.86 million in shares - Investing.com
Leerink Partnrs Analysts Raise Earnings Estimates for WVE - MarketBeat
Wave Life Sciences Rockets 70% On Historic RNA Editing Success - Barchart
WVE (WAVE Life Sciences) Change In Inventory : $0.0 Mil (TTM As of Jun. 2024) - GuruFocus.com
WVE (WAVE Life Sciences) Earnings per Share (Diluted) : $-0.57 (TTM As of Jun. 2024) - GuruFocus.com
Wave Life Sciences (NASDAQ:WVE) Shares Gap DownHere's What Happened - MarketBeat
Wave Life Sciences Shares Surge After RNA Editing Discovery - Yahoo Finance
JPMorgan Chase & Co. Increases Wave Life Sciences (NASDAQ:WVE) Price Target to $17.00 - MarketBeat
Wave claims first clinical RNA editing title in rare genetic disease - BioPharma-Reporter.com
Takeda terminates deal with Wave - The Pharma Letter
Wave Life Sciences (NASDAQ:WVE) Receives Buy Rating from HC Wainwright - MarketBeat
WAVE Life Sciences stock's Buy rating and price target reaffirmed by H.C. Wainwright - Investing.com UK
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last? - Yahoo Finance
WVE Stock Soars 74% as Wave Life Sciences Achieves RNA Editing Breakthrough - MoneyCheck
Wave surges on first RNA editing data in humans - pharmaphorum
Wave data propel RNA-editing stocks, but are all platforms created equal? - BioCentury
WAVE Life Sciences (FRA:1U5) 50-Day SMA : €5.85 (As of Oct. 16, 2024) - GuruFocus.com
Jones Trading keeps WAVE Life Sciences at Buy, target at $20 - Investing.com India
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Francis Chris | See Remarks |
Oct 16 '24 |
Sale |
13.67 |
208,836 |
2,855,051 |
0 |
| BOLNO PAUL | President and CEO |
Oct 16 '24 |
Sale |
15.00 |
90,474 |
1,357,110 |
268,585 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):